Related Experiment Video
Updated: May 16, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Cardiovascular risk assessment: addition of CKD and race to the Framingham equation
Paul E Drawz1, Sarah Baraniuk, Barry R Davis
1MetroHealth Medical Center, Cleveland, OH, USA. draw0003@umn.edu
Insights
Adding chronic kidney disease (CKD) status and race to the Framingham equation does not improve cardiovascular risk prediction in hypertensive patients. This finding applies to diverse patient groups, including African Americans.
Area of Science:
- Cardiology
- Nephrology
- Epidemiology
Background:
- The Framingham equation is widely used for cardiovascular risk prediction.
- Its accuracy in African Americans and patients with chronic kidney disease (CKD) is uncertain.
- Hypertension management requires precise risk stratification.
Purpose of the Study:
- To assess if incorporating CKD and race improves the Framingham equation's risk prediction in hypertensive individuals.
- To evaluate the enhanced model's performance across different racial groups and in patients with CKD.
Main Methods:
- Utilized data from 19,811 eligible participants in the ALLHAT study.
- Developed two Cox proportional hazards models: one with traditional Framingham factors, and another including CKD and race.
- Validated models using C-statistics and net reclassification improvement.
Main Results:
- No significant difference in C-statistics between the standard Framingham equation and the enhanced model (including CKD and race) was observed.
- This held true across racial subgroups, sexes, and individuals with CKD.
- Net reclassification improvement was not significant for any subgroup.
Conclusions:
- The addition of CKD status and race stratification does not enhance cardiovascular risk prediction in high-risk hypertensive patients.
- Current risk prediction models may need further refinement for diverse populations.
Background/Aims:
The value of the Framingham equation in predicting cardiovascular risk in African Americans and patients with chronic kidney disease (CKD) is unclear. The purpose of the study was to evaluate whether the addition of CKD and race to the Framingham equation improves risk stratification in hypertensive patients.
Methods:
Participants in the ALLHAT were studied. Those randomized to doxazosin, older than 74 years, and those with a history of coronary heart disease were excluded. Two risk stratification models were developed using Cox proportional hazards models in a two-thirds developmental sample. The first model included the traditional Framingham risk factors. The second model included the traditional risk factors plus CKD, defined by estimated glomerular filtration rate categories, and stratification by race (black vs non-black). The primary outcome was a composite of fatal coronary heart disease, nonfatal myocardial infarction, coronary revascularization, and hospitalized angina.
Results:
There were a total of 19,811 eligible subjects. In the validation cohort, there was no difference in C-statistics between the Framingham equation and the ALLHAT model including CKD and race. This was consistent across subgroups by race and sex and among those with CKD. One exception was among Non-Black women where the C-statistic was higher for the Framingham equation (0.68 vs 0.65, P = .02). In addition, net reclassification improvement was not significant for any subgroup based on race and sex, ranging from -5.5% to 4.4%.
Conclusion:
The addition of CKD status and stratification by race does not improve risk prediction in high-risk hypertensive patients.
Related Concept Videos
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease I: Introduction
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
